FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Cobenfy Effective as Schizophrenia Adjunct: Trial

Bristol Myers Squib says its Cobenfy showed positive results in the Phase 3 ARISE trial as an adjunctive therapy to atypical antipsychotics for patien...

latest-news-card-1
Human Drugs

Update Drug Labels with Obesity Info: Pitts

Former FDA associate commissioner Peter Pitts calls on the agency to revise drug labels with obesity safety and effectiveness information.

latest-news-card-1
Human Drugs

Lilly Sues 4 More Weight-Loss Drug Compounders

Lilly sues four additional drug compounders for illegally selling copies of its weight loss and diabetes drugs.

latest-news-card-1
Medical Devices

Alert Issued on Conavis Novasight Catheters

The catheter is part of a system intended for intravascular imaging of coronary arteries.

Biologics

FDA Seeks Post-Marketing Commitment from Novavax

Novavax says its Covid-19 vaccine BLA is being held up while FDA seeks to conclude a post-marketing commitment from the company.

Medical Devices

CereVasc Gains Breakthrough Status for eShunt

FDA grants CereVasc a breakthrough device designation for its investigational eShunt System and its use in treating communicating hydrocephalus.

latest-news-card-1
FDA General

ESG NextGen is Live: FDA

FDA says its Electronic Submission Gateway Next Generation is live and ready to receive submissions.

latest-news-card-1
Human Drugs

Vanda Criticizes FDA on Tradipitant Hearing Delay

Vanda Pharmaceuticals criticizes FDA for wrongly claiming that recent staff cuts and a new commissioner causes it to delay a company request for a hea...

latest-news-card-1
Human Drugs

Akesos Ivonescimab Meets Endpoint in Lung Cancer

Akeso says its ivonescimab met the primary endpoint in a pivotal Phase 3 trial for the first-line treatment of advanced squamous non-small cell lung c...

latest-news-card-1
Medical Devices

ICU Medical Illegally Marketing Devices: FDA

FDA warns ICU Medical that its Minneapolis, MN-based Smiths Medical ASD unit is illegally marketing adulterated and misbranded infusion pumps.